AFT Pharmaceuticals Limited (NZX: AFT) 24-hour Efficacy for Crystawash Extend Hand Sanitiser

Monday 11th January 2021

AFT Pharmaceuticals today announces independent laboratories have found that its new Crystawash Extend Hand Sanitiser:

• Displays 24-hour residual efficacy against germs evidenced by testing on synthetic skin against S.Aureus and E.Coli

• Kills 99.99% of germs on immediate contact being S.Aureus, E.Coli, P.aeruginosa, and E. hirae

• Meets the accepted standard for killing Corona virus, evidenced by activity against the Corona virus surrogate [Murine hepatitis virus (MHV1)

The newly developed, ethanol free, foaming formulation adds to AFT’s existing Crystawash sanitiser range in Australia and New Zealand and meets the huge demand for hand sanitiser that has emerged with the Covid-19 pandemic. It also enhances the appeal of AFT’s over-the-counter portfolio of medicines, now sold in more than 6,000 pharmacies and other outlets across Australasia.

Dr Atkinson said Crystawash Extend sales will add to this financial year’s results in Australia and New Zealand and also has potential around the world as AFT leverages its global network of partners to out-license the product in other jurisdictions. Already Canada’s CombomedPharma Inc has agreed to distribute Crystawash Extend in that country and more agreements are expected to follow.

See the links below for more details:

24-hour efficacy for Crystawash Extend Hand Sanitiser

Source: AFT Pharmaceuticals Limited

Comments from our readers

No comments yet